SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the ...

MONDAY, Dec. 16, 2024 (HealthDay News) -- The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast ...

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their ...

The estimated 15-year risk of ipsilateral recurrence was 11.4% for patients treated with tamoxifen and 19% for patients who did not receive tamoxifen, a statistically significant difference. When ...

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus the effectiveness of the drug. The finding, published in the journal mBio of ...

Women taking a new breast cancer drug are living longer than those taking Tamoxifen - the current 'gold standard' treatment. Doctors predict the new drug, Arimidex, will improve long-term survival ...

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus the effectiveness of the drug. The finding, published in the journal mBio ...

Switching to an AI following 2–3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI. This article evaluates the most up-to-date results ...

Weekly administration of prophylactic tamoxifen is much less effective than the standard daily regimen in preventing the adverse breast effects induced by bicalutamide. Bicalutamide monotherapy is ...

Tamoxifen treatment has been linked to an excess risk of nonalcoholic steatohepatitis, which is characterized by inflammation and fatty deposits in the liver. Bruno and colleagues have ...

Citation: Clinical trial: Adjuvant tamoxifen may reduce recurrence risk for patients with 'good-risk' DCIS who forgo radiation (2024, December 12) retrieved 6 January 2025 from https ...